Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial

Abstract Objectives Currently, there are no approved treatments for early disease stages of COVID-19 and few strategies to prevent disease progression after infection with SARS-CoV-2. The objective of this study is to evaluate the safety and efficacy of convalescent plasma (CP) or camostat mesylate...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Verena Keitel, Björn Jensen, Torsten Feldt, Johannes C. Fischer, Johannes G. Bode, Christiane Matuschek, Edwin Bölke, Wilfried Budach, Christian Plettenberg, Kathrin Scheckenbach, Detlef Kindgen-Milles, Jörg Timm, Lisa Müller, Henrike Kolbe, Andreas Stöhr, Christian Calles, Andreas Hippe, Pablo Verde, Christoph D. Spinner, Jochen Schneider, Timo Wolf, Winfried V. Kern, Jacob Nattermann, Alexander Zoufaly, Christian Ohmann, Tom Luedde, RES-Q-HR Trial Team
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-05-01
coleção:	Trials
Assuntos:	COVID-19 Randomized controlled trial Protocol Convalescent plasma Camostat mesylate Antiviral therapy
Acesso em linha:	https://doi.org/10.1186/s13063-021-05181-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!